How good are we at preventing HIV? How do efficacy and effectiveness differ? We journey from oral pre-exposure prophylaxis (PrEP) to long-acting injectables , and then to the PURPOSE trials , which look at the use of long-acting lenacapavir as PrEP — a potential game-changer in the field of HIV . Listen to this latest episode of Beyond Journal Club , a collaboration between CoreIM and NEJM Group , where we put research into context , telling the story of how we arrived at the current standard of care , appreciating the clinical question of the trial at hand, and interpreting what the findings may mean for these patients . 🔹 Sponsor : NEJM Fellowship Program, click here to learn more and/or apply ! 🔹 Transcript and Show Notes Timestamps: (02:25) | HIV PrEP Daily Truvada and Descovy (07:48) | On-Demand Prep (13:25) | Purpose Trials (20:56) | Discussion of Effectiveness to Efficacy Tags: CoreIM, Internal Medicine, Primary Care, Medical Education, IMCore, Physician Assistant, Nurse Practitioner, Medical Student, HIV Prevention, Infectious Disease Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840 Our Sponsors: * Check out Branch Basics and use the code COREIM for 15% off: https://branchbasics.com * Check out FIGS and use code FIGSRX for a great deal: https://wearfigs.com * Check out Tempo Meals for 60% Off: https://tempomeals.com/COREIM * Check out Uncommon Goods for 15% off: https://uncommongoods.com/COREIM * Check out Washington Red Raspberries: https://redrazz.org Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy
